AstraZeneca mulls €240bn mega-merger with Gilead Sciences
Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.
Free, fast, fair
Continue reading this article and get instant access to even more investment news by registering your details below: